ReviewCells2023
Heterogeneity of Cholangiocarcinoma Immune Biology.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer.Cancer science · 2024Trial
- Advances in the Molecular Mechanisms of Cholangiocarcinoma: A Comprehensive Review of Biomarkers, Regulatory Pathways and Tumor Microenvironment Reprogramming.International journal of molecular sciences · 2026Review
- Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2026Review
- Comprehensive analysis of disulfidptosis-related genes identifies clinically actionable prognostic biomarkers in cholangiocarcinoma.Discover oncology · 2026Article
- Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.International journal of medical sciences · 2026Article
- Cancer-Associated Fibroblasts in Gastrointestinal Cancer Metastasis: Mechanisms and Emerging Therapeutic Strategies.Drug design, development and therapy · 2026Review
- New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas.Journal of hepatology · 2025Article
- Changing patterns of cholangiocarcinoma and gallbladder cancer: A regional perspective from Northeastern Italy.World journal of gastrointestinal oncology · 2025Article
- Role, mechanism, and application of N6-methyladenosine in hepatobiliary carcinoma.World journal of gastrointestinal oncology · 2025Review
- PPIH is a novel diagnostic biomarker associated with immune infiltration in cholangiocarcinoma.BMC cancer · 2025Article
- Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights.Experimental hematology & oncology · 2025Review
- Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Frontiers in immunology · 2025Review
- Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on "Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma".Clinical and molecular hepatology · 2025Article
- Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface.Virchows Archiv : an international journal of pathology · 2024Article
- Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.Clinical and experimental medicine · 2024Review
- Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome.JCO precision oncology · 2024Article
- Review
- From mechanism to therapy: the journey of CD24 in cancer.Frontiers in immunology · 2024Review
- Case report: From palliative to potentially curative - the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma.Frontiers in immunology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinomas (CCAs) are aggressive tumors arising along the biliary tract epithelium, whose incidence and mortality are increasing. CCAs are highly desmoplastic cancers characterized by a dense tumor microenvironment (TME), in which each single component plays a fundamental role in shaping CCA initiation, progression and resistance to therapies. The crosstalk between cancer cells and TME can affect the recruitment, infiltration and differentiation of immune cells. According to the stage of the disease and to intra- and inter-patient heterogeneity, TME may contribute to either protumoral or antitumoral activities. Therefore, a better understanding of the effect of each immune cell subtype may open the path to new personalized immune therapeutic strategies for the management of CCA. In this review, we describe the role of immune cells in CCA initiation and progression, and their crosstalk with both cancer-associated fibroblasts (CAFs) and the cancer-stem-cell-like (CSC) niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.